Join to invest

Already registered? Log in

107%

RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities.

  • First commercial contract agreed
  • Over 800 members with rare cancer & 3 charity partnerships in place
  • NHS Ethics approved process for collecting & sequencing samples
  • Chief Technology Officer appointed
Information £300k of funds on the progress bar represent funds raised by the Company prior to launching the campaign. The Company has already received these funds, shares have been issued, and the Company has indicated up to £10k may be spent whilst the pitch is live. Completion of the Crowdcube raise will occur on the same material terms and share price.

Idea

Every day around 1000 people in the UK are told they have cancer. For an est. 1 in 5 their cancer is too rare for the best treatment to be clear because of insufficient research.

We believe there's an opportunity to change this. Although treatments targeting rare cancers represent 63% of the oncology trials in 2020, recruiting enough patients to test them is a challenge for the $49bn Contract Research Organisation (CRO) industry that supports trial delivery.

RareCan aims to be a solution to this problem. RareCan is a direct-to-patient clinical trial platform, bringing together patients and their clinical, laboratory and genetic data, aiming to increase speed of recruitment, reduce screen failure and increase retention rates for trials.

We have recruited over 800 people with rare cancers; received NHS ethics approval for the process of collecting samples for our BioResource and started genetic sequencing of cancer samples from our members; we have a commercial contract agreed and a confidentiality agreement in place with 3 of the world's largest CRO's.

We are raising funds with the aim of growing our team, expanding our marketing and developing our platform to provide trial recruitment services to help accelerate the rate at which new treatments are made available with the aim of helping to improve outcomes for millions of people living with rare cancers.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the RareCan pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

RareCan has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.